ArticlemedRxiv : the preprint server for health sciences2026
PRE-CISE: A PRE-calibration Coverage, Identifiability, and SEnsitivity analysis workflow to streamline model calibration.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Purpose: We introduce PRE-CISE, a pre-calibration workflow that integrates coverage analysis, local sensitivity, and collinearity diagnostics to streamline model calibration and transparently address nonidentifiability. We demonstrate the benefits of PRE-CISE using a four-state Sick-Sicker Markov testbed and a COVID-19 case study. Methods: PRE-CISE begins with a coverage analysis to verify that model outputs generated with parameter sets drawn from their prior distribution span calibration targets, followed by local sensitivities to quantify the influence of parameters on model outputs, guiding the resizing of the prior distribution bounds to improve coverage. Identifiability is then assessed via collinearity analysis; large indices indicate practical nonidentifiability. For the testbed model, we calibrated 3 parameters to survival, prevalence, and the proportion of Sick to Sicker at 10, 20, and 30 years. For the COVID-19 model, we calibrated 11 parameters to match daily confirmed incident cases. Bayesian calibration was conducted on both analyses. Results: Coverage analyses flagged initial misfits; local sensitivities identified the Sick-to-Sicker transition probability has a greater effect on model outputs, and resizing its prior distribution bounds improved coverage. Collinearity analyses showed that combining multiple calibration targets across time points enabled recovery of all three parameters. In the COVID-19 model, local sensitivity analyses prioritized time-varying detection rates and contact-reduction effects, reducing the search space, thereby improving calibration efficiency. Daily incident case calibration targets yielded collinearity indices below practical thresholds (e.g., < 15) for all parameter combinations, whereas weekly calibration targets were larger and closer to the cutoff. Conclusions: PRE-CISE provides a practical, transparent pathway that helps modelers refine prior distribution bounds and calibration targets before intensive calibration, improving uncertainty reporting and strengthening the reliability of model-based health policy analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.